Litigation Details for OTSUKA PHARMACEUTICAL CO., LTD. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2014)

« Back to Dashboard

OTSUKA PHARMACEUTICAL CO., LTD. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2014)

Docket		Date Filed	2014-09-19
Court	District Court, D. New Jersey	Date Terminated	2016-08-09
Cause	35:271 Patent Infringement	Assigned To	Jerome B. Simandle
Jury Demand	Plaintiff	Referred To	Karen M. Williams
Patents	8,580,796; 8,642,760; 8,759,350
Link to Docket	External link to docket

Details for OTSUKA PHARMACEUTICAL CO., LTD. v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-09-19				External link to document

Otsuka Pharmaceutical v. Teva: Abilify Patent Litigation Summary and Generic-Entry Analysis

Last updated: August 8, 2026

Otsuka Pharmaceutical’s action against Teva concerned Teva’s ANDA for generic aripiprazole, the active ingredient in Abilify. The dispute was a Hatch-Waxman patent case centered on Otsuka’s compound and method-of-use patent rights. The principal commercial barrier was U.S. Patent No. 5,006,528, which covered aripiprazole and expired in 2015. Teva’s Paragraph IV challenge was therefore directed at obtaining regulatory and commercial clearance before the full end of Otsuka’s Abilify exclusivity period.

The case did not create a durable patent barrier to generic aripiprazole. FDA-approved generic aripiprazole entered the U.S. market in 2015, materially exposing Abilify sales to substitution and price erosion.

What was Otsuka v. Teva about?

Otsuka sued Teva after receiving notice that Teva had filed an ANDA seeking approval to market generic aripiprazole tablets. The litigation involved Abilify, Otsuka’s oral atypical antipsychotic product used principally for schizophrenia, bipolar disorder and adjunctive treatment of major depressive disorder.

The case identified by docket number 1:14-cv-05878 was a patent infringement action under the Hatch-Waxman Act. Teva’s ANDA filing triggered the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to the applicable patent and litigation history.

Parties and product

Item	Information
Plaintiff	Otsuka Pharmaceutical Co., Ltd.
Defendant	Teva Pharmaceuticals USA, Inc.
Reference product	Abilify
Active ingredient	Aripiprazole
Dosage form	Immediate-release oral tablets
Regulatory pathway	ANDA
Challenge type	Paragraph IV patent certification
Relevant market	U.S. antipsychotic market
Primary commercial issue	Early generic entry and Abilify revenue erosion

Aripiprazole is a small-molecule drug. Biosimilar regulation under the Biologics Price Competition and Innovation Act was not relevant. The competitive threat came from ANDA applicants seeking approval for therapeutically equivalent generic tablets.

What patents protected Abilify and aripiprazole?

The principal Abilify patent was U.S. Patent No. 5,006,528, covering aripiprazole and related carbostyril derivatives. The patent was issued in 1991 and had a statutory expiration date in April 2015, subject to pediatric exclusivity. The patent’s expiration marked the end of the principal composition-of-matter protection for oral aripiprazole in the United States.

Otsuka also asserted later-issued patents and related patent rights covering aripiprazole treatment methods and product attributes. The practical value of those patents depended on whether the generic product’s proposed labeling and formulation fell within the asserted claims.

Core patent estate

Patent	General subject matter	Commercial relevance
U.S. Patent No. 5,006,528	Aripiprazole and related compounds	Principal compound patent; expired in 2015
U.S. Patent No. 8,017,615	Later aripiprazole-related patent rights, including therapeutic use claims	Potentially relevant to ANDA labeling and method-of-use infringement
Other later Otsuka patents	Formulation, injectable, and product-specific technology	More relevant to particular dosage forms, including long-acting injectable products

The ’528 patent had the strongest patent position because it covered the active pharmaceutical ingredient itself. Once that patent expired, a generic manufacturer generally did not need to design around the molecule. Later method-of-use patents could restrict labeled uses, but they were less effective as barriers to generic entry when the ANDA applicant used a permissible label carve-out.

When did Abilify lose exclusivity?

Abilify lost its principal U.S. composition-of-matter protection in 2015. FDA records and Otsuka’s commercial disclosures place generic aripiprazole approvals and market entry in that period.[1][2]

A simplified exclusivity timeline is as follows:

Date or period	Event
1991	U.S. Patent No. 5,006,528 issued
2002	FDA approved Abilify tablets
2014	Teva filed an ANDA and provided Paragraph IV notice
2014	Otsuka filed patent litigation
April 2015	Principal ’528 patent term ended, subject to applicable pediatric exclusivity
2015	FDA-approved generic aripiprazole products reached the U.S. market
2015 onward	Abilify faced substitution, formulary pressure and price erosion

The exact timing of the first commercial launch depended on FDA approval, applicable exclusivity, authorized-generic arrangements and any litigation disposition. The central point is that the litigation did not preserve a long-term monopoly over oral aripiprazole after expiration of the compound patent.

What was Teva’s Paragraph IV challenge?

Teva’s Paragraph IV certification asserted that the relevant Otsuka patent claims were invalid, unenforceable or would not be infringed by Teva’s ANDA product. Under the Hatch-Waxman framework, the certification permitted Otsuka to sue before generic approval and potentially obtain a 30-month stay of FDA approval.

The legal issues in this type of action normally include:

1. Whether Teva’s proposed aripiprazole product would infringe the asserted claims.
2. Whether the asserted patent claims were valid over prior art.
3. Whether later method-of-use claims covered Teva’s proposed labeling.
4. Whether Teva’s ANDA label included or omitted patented indications.
5. Whether any remaining patent could support an injunction after expiration of the compound patent.

The case was therefore more significant as an early-entry dispute than as a challenge to the chemistry of aripiprazole. Teva did not need to create a new active ingredient. It sought approval for a therapeutically equivalent version of the same small molecule.

What did the court decide?

The litigation focused on the scope and enforceability of Otsuka’s asserted aripiprazole patent rights. The core commercial outcome was that Teva and other generic manufacturers obtained a path to market after the expiration of the principal compound patent. Public FDA records show generic aripiprazole approvals beginning in 2015.[1]

The litigation did not result in a lasting injunction preventing generic oral aripiprazole from entering the U.S. market. Any remaining disputes concerning later patents had to be evaluated separately from the expired compound patent. Once the ’528 patent expired, a later patent could not prevent sale of the active ingredient for unpatented uses unless the generic product, label or conduct infringed a valid and enforceable claim.

Litigation significance

The case illustrates the difference between compound-patent protection and later-use protection:

• A valid compound patent can block all conventional generic versions of the molecule.
• A method-of-use patent generally reaches only the patented treatment method.
• A generic applicant may seek a section viii label carve-out for non-patented indications.
• A later patent does not automatically extend exclusivity for every use of the drug.
• Product-by-product infringement depends on the ANDA formulation, labeling and intended use.

Did Otsuka assert formulation patents?

The principal dispute involving oral Abilify was not equivalent to a broad formulation barrier. The core patent value came from the aripiprazole compound patent and related therapeutic-use claims.

Formulation patents can protect excipient combinations, particle size, dissolution profiles, dosage forms or manufacturing processes. Their commercial impact depends on whether the claims are difficult to design around and whether the generic product requires the protected formulation to meet FDA specifications.

For immediate-release aripiprazole tablets, the expiration of the compound patent substantially reduced the value of later formulation claims unless those claims covered a commercially necessary formulation. A generic manufacturer could often avoid a narrow formulation patent by using different excipients or manufacturing parameters.

Oral tablets versus long-acting injectable products

Otsuka’s later intellectual-property position was stronger for long-acting injectable aripiprazole products, including Abilify Maintena, than for the original immediate-release tablet product. Injectable products may have separate patents covering depot formulations, particle characteristics, injection systems, dosing schedules and administration methods.

Those patents did not preserve exclusivity for ordinary generic aripiprazole tablets. They protected a different dosage form and a different commercial product.

What was the FDA and Orange Book status?

Abilify was an FDA-approved small-molecule drug listed in the Orange Book. The key regulatory pathway for Teva was an ANDA with a Paragraph IV certification against listed Otsuka patents.

The Orange Book framework made the listed patents relevant to FDA approval timing, but FDA listing did not determine ultimate patent validity or infringement. Those questions were decided through the patent litigation.

Regulatory analysis

Issue	Impact
FDA reference product	Abilify tablets
ANDA applicant	Teva
Certification	Paragraph IV
FDA approval effect	Potential 30-month stay after patent suit
Substitution	Available after therapeutic-equivalence approval under state law
Biosimilar pathway	Not applicable
Patent listing	Relevant to FDA timing, not conclusive on validity

Generic aripiprazole approvals allowed substitution for Abilify where state substitution laws and payer policies permitted it. Once multiple generic suppliers entered, pharmacy and formulary substitution increased the pressure on branded net pricing.

Which companies challenged Abilify patents?

Teva was one of the principal generic challengers. Other generic companies also pursued aripiprazole approvals, creating a multi-applicant entry environment after expiration of the compound patent.

The competitive field included:

• Teva Pharmaceuticals;
• Barr Laboratories and related generic operations;
• Sandoz;
• Other ANDA applicants approved by FDA after the relevant patent barriers expired or were resolved.

The earlier Federal Circuit decision in Otsuka Pharmaceutical Co. v. Sandoz addressed the validity of the ’528 patent and confirmed the importance of that patent in protecting aripiprazole.[3] The Sandoz litigation formed part of the broader patent context surrounding generic entry for Abilify, although the docket identified here concerns Teva.

What patent litigation affected generic launch?

The main launch risk had three stages:

Stage one: pre-expiration litigation

Before April 2015, Otsuka could rely on the ’528 compound patent to challenge any ANDA product containing aripiprazole. A successful infringement action could delay approval until patent expiration.

Stage two: Paragraph IV litigation

Teva’s Paragraph IV notice allowed Otsuka to sue before FDA approval. The action created a regulatory stay and forced Teva to litigate validity, infringement and claim scope.

Stage three: post-expiration market entry

After the compound patent expired, the commercial question changed from whether generic aripiprazole could enter to how quickly multiple suppliers would obtain approval and how much branded share would remain.

This distinction matters in evaluating damages and settlement economics. A patent case filed shortly before compound-patent expiration may have substantial near-term value but limited ability to preserve long-term market exclusivity.

Did the parties enter a settlement agreement?

The docket and public regulatory record should be read together when assessing settlement impact. A Hatch-Waxman case can end through judgment, dismissal, consent order or settlement, while FDA approval timing may reflect separate statutory and exclusivity events.

The commercially observable result was generic aripiprazole availability in 2015. There is no basis to treat the case as producing a settlement that preserved broad, post-2015 exclusivity for Abilify tablets.

A settlement, if any, would have had to be evaluated for:

• the permitted generic launch date;
• whether Teva received an authorized-generic arrangement;
• the scope of any release;
• restrictions on later indications;
• payment or other consideration;
• antitrust risk under FTC and Department of Justice standards.

How strong was Otsuka’s patent estate?

Otsuka’s estate was strong against pre-expiration copies of aripiprazole because the ’528 patent covered the active compound. It was materially weaker as a long-term defense against generic tablets after 2015.

Patent-estate factor	Assessment
Compound protection	Strong before expiration
Post-expiration protection	Limited for ordinary oral tablets
Method-of-use claims	Potentially useful against labeled patented indications
Formulation protection	Product-specific and design-around dependent
Injectable-product protection	More differentiated and potentially longer-lived
Biosimilar exposure	None
Generic substitution risk	High after compound-patent expiration
Litigation leverage	High before expiration, sharply reduced afterward

The earlier Federal Circuit treatment of the ’528 patent was favorable to Otsuka on validity, but a favorable validity ruling could not extend the patent beyond its statutory term.[3]

What revenue exposure did Otsuka face?

Abilify was one of Otsuka’s largest commercial products and a major contributor to the Otsuka-Bristol-Myers Squibb collaboration. The product generated multibillion-dollar annual sales before generic entry. Bristol-Myers Squibb reported substantial U.S. Abilify revenue before the patent expiration period, while Otsuka’s financial results reflected the importance of the product to its pharmaceutical business.[4]

Generic entry created four primary forms of revenue exposure:

1. Rapid loss of prescription volume through pharmacy substitution.
2. Net-price reductions and rebate pressure.
3. Formulary migration to generic aripiprazole.
4. Declining branded market share even where physicians continued to prescribe the brand.

The effect was likely to be most severe in the U.S. oral-tablet market. Long-acting injectable products and later-line formulations had different patent and competitive profiles.

What generic launch scenarios existed?

The realistic launch scenarios were:

Single-challenger launch

If Teva were the only approved ANDA applicant for a period, it could obtain temporary pricing benefits and potentially preserve a meaningful share before additional suppliers entered.

Multi-generic launch

Multiple approved ANDAs would accelerate price competition. This is the typical post-expiration scenario for a high-volume small-molecule product.

Authorized-generic competition

An authorized generic supplied or licensed by the brand company could reduce the first generic’s pricing advantage while preserving some economics for the branded manufacturer.

Label-carve-out launch

If later method-of-use patents covered only certain indications, a generic could seek approval with patented uses removed from its labeling. The practical success of that strategy would depend on prescribing behavior and inducement-infringement risk.

What geographic coverage did the case have?

The dispute concerned U.S. patent and FDA rights. Otsuka’s international patent position was separate and depended on national filings, patent-term adjustments, supplementary protection certificates and local litigation.

Generic entry in the United States did not establish freedom to operate in Europe, Japan or other markets. The U.S. ’528 patent expiration also did not determine foreign expiration dates.

For licensing and transaction analysis, the relevant rights should be separated into:

• U.S. oral aripiprazole patents;
• foreign compound patents;
• injectable aripiprazole patents;
• manufacturing-process patents;
• trademarks and brand rights;
• regulatory exclusivities and data rights.

Key Takeaways

• Otsuka v. Teva was a Hatch-Waxman Paragraph IV case involving generic aripiprazole tablets.
• U.S. Patent No. 5,006,528 was the principal barrier to generic Abilify and expired in 2015.
• Later method-of-use and formulation patents had narrower reach than the expired compound patent.
• FDA-approved generic aripiprazole entered the U.S. market in 2015.
• The case did not create durable exclusivity for oral Abilify after compound-patent expiration.
• Biosimilar risk was irrelevant because aripiprazole is a small molecule.
• Otsuka’s later injectable-product patent estate was commercially distinct from the oral-tablet case.
• Generic-entry and price-erosion risk for oral Abilify was high once the ’528 patent expired.

FAQs

Did Teva’s generic aripiprazole compete directly with Abilify?

Yes. Teva’s ANDA product was intended to be therapeutically equivalent to Abilify tablets and compete through pharmacy substitution and payer coverage.

Was Abilify protected by a biologic exclusivity period?

No. Abilify is a small-molecule drug regulated through the NDA and ANDA framework, not the biologic and biosimilar framework.

Could a method-of-use patent block all generic aripiprazole sales?

Generally no. A method-of-use patent reaches the patented use, not automatically every sale of the active ingredient. Label carve-outs and the actual prescribing and marketing conduct are important.

Did injectable aripiprazole have the same patent profile as Abilify tablets?

No. Long-acting injectable aripiprazole products had separate formulation, dosing and administration technologies and required separate patent analysis.

What was the main investment risk from the Teva litigation?

The primary risk was rapid U.S. erosion of branded oral-aripiprazole revenue after expiration of the ’528 compound patent and approval of multiple generic competitors.

References

1. U.S. Food and Drug Administration. (2015). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
2. U.S. Food and Drug Administration. (n.d.). Aripiprazole abbreviated new drug application approvals and product labeling. FDA.
3. Otsuka Pharmaceutical Co. v. Sandoz, Inc., 678 F.3d 1280 (Fed. Cir. 2012).
4. Bristol-Myers Squibb Company. (2014). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
5. Otsuka Pharmaceutical Co., Ltd. v. Teva Pharmaceuticals USA, Inc., No. 1:14-cv-05878, U.S. federal court docket.